Viewing Study NCT01780935


Ignite Creation Date: 2025-12-24 @ 10:14 PM
Ignite Modification Date: 2026-01-05 @ 3:51 PM
Study NCT ID: NCT01780935
Status: COMPLETED
Last Update Posted: 2017-08-14
First Post: 2013-01-29
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neovascular Age-related Macular Degeneration View
Keywords: